NASDAQ:CHMA - Chiasma Stock Price, Forecast & News

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

Chiasma Inc (NASDAQ:CHMA) posted its quarterly earnings results on Tuesday, November, 5th. The biotechnology company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.01. View Chiasma's Earnings History.

Chiasma is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Chiasma.

6 equities research analysts have issued 1 year price objectives for Chiasma's shares. Their forecasts range from $11.00 to $18.00. On average, they expect Chiasma's share price to reach $13.80 in the next twelve months. This suggests a possible upside of 199.3% from the stock's current price. View Analyst Price Targets for Chiasma.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chiasma in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chiasma.

Press coverage about CHMA stock has been trending very negative recently, according to InfoTrie Sentiment. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Chiasma earned a coverage optimism score of -3.7 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Chiasma.

Chiasma saw a decrease in short interest in January. As of January 31st, there was short interest totalling 1,600,000 shares, a decrease of 10.1% from the January 15th total of 1,780,000 shares. Based on an average trading volume of 275,500 shares, the short-interest ratio is presently 5.8 days. Approximately 5.3% of the shares of the stock are short sold. View Chiasma's Current Options Chain.

Some companies that are related to Chiasma include Frequency Therapeutics (FREQ), DiaMedica Therapeutics (DMCAF), Provention Bio (PRVB), Eagle Pharmaceuticals (EGRX), G1 Therapeutics (GTHX), Retrophin (RTRX), Cara Therapeutics (CARA), Akero Therapeutics (AKRO), Vanda Pharmaceuticals (VNDA), TherapeuticsMD (TXMD), BioXcel Therapeutics (BTAI), Emisphere Technologies (EMIS), Aprea Therapeutics (APRE), RAPT Therapeutics (RAPT) and Omeros (OMER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chiasma investors own include Arbutus Biopharma (ABUS), Bausch Health Companies (BHC), GW Pharmaceuticals PLC- (GWPH), BioDelivery Sciences International (BDSI), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), Skyworks Solutions (SWKS), Viking Therapeutics (VKTX), Zynerba Pharmaceuticals (ZYNE) and Agile Therapeutics (AGRX).

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Chiasma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (3.57%), Ikarian Capital LLC (2.63%), State Street Corp (1.42%), Renaissance Technologies LLC (1.37%), J. Goldman & Co LP (0.83%) and Bank of New York Mellon Corp (0.25%). Company insiders that own Chiasma stock include Mark J Fitzpatrick, Roni Mamluk, Scott Minick and William Ludlam. View Institutional Ownership Trends for Chiasma.

CHMA stock was sold by a variety of institutional investors in the last quarter, including J. Goldman & Co LP and Point72 Asset Management L.P.. View Insider Buying and Selling for Chiasma.

CHMA stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, State Street Corp, California Public Employees Retirement System, Barclays PLC, ProShare Advisors LLC, UBS Group AG, Virtu Financial LLC and Alambic Investment Management L.P.. Company insiders that have bought Chiasma stock in the last two years include Mark J Fitzpatrick, Scott Minick and William Ludlam. View Insider Buying and Selling for Chiasma.

Shares of CHMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHMA stock can currently be purchased for approximately $4.61.

Chiasma has a market capitalization of $193.71 million. The biotechnology company earns $-31,260,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis. Chiasma employs 18 workers across the globe.View Additional Information About Chiasma.

The official website for Chiasma is http://www.chiasmapharma.com/.

Chiasma's mailing address is 460 Totten Pond Road Suite 530, Waltham MA, 02451. The biotechnology company can be reached via phone at 617-928-5300 or via email at [email protected]